As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

A major new study has highlighted significant health risks associated with popular weight loss injections such as Ozempic, Wegovy, and Mounjaro. The research involved over two million patients and found that those using these medications have double the risk of developing pancreatitis – a potentially life-threatening inflammation of the pancreas.

Recent research reveals that weight-loss injections reduce the risk of 42 health conditions in people with diabetes, potentially paving the way for broader treatments.

Weight-loss jabs could reduce your risk of drug abuse, seizures and pneumonia, as well as heart attacks and strokes, scientists have found. Last year, research revealed that weight-loss jabs – or GLP-1RAs – such as Wegovy and Ozempic could reduce the risk of heart attack and stroke.

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia. But these drugs also come with risks that shouldn't be overlooked,

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,

A new study reveals that popular diabetes and weight loss medications like Ozempic and Wegovy may offer unexpected health benefits, from reducing addiction risk to protecting against Alzheimer’s disease.